CN Patent

CN102153505A — N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n’-(4-(2-甲基丙氧基)苯基甲基)脲及其酒石酸盐的合成和晶形

Assigned to Acadia Pharmaceuticals Inc · Expires 2011-08-17 · 15y expired

What this patent protects

本发明公开了式IV的N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-(2-甲基丙氧基)-苯基甲基)脲酒石酸盐的晶型，包含该晶型的组合物及其用途。

USPTO Abstract

本发明公开了式IV的N-(4-氟苄基)-N-(1-甲基哌啶-4-基)-N’-(4-(2-甲基丙氧基)-苯基甲基)脲酒石酸盐的晶型，包含该晶型的组合物及其用途。

Drugs covered by this patent

pimavanserin-tartrate (PIMAVANSERIN TARTRATE)

Patent Metadata

Patent number: CN102153505A
Jurisdiction: CN
Classification: —
Expires: 2011-08-17
Drug substance claim: No
Drug product claim: No
Assignee: Acadia Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.